According to a post on the FDA’s website, Ionis Pharmaceuticals’ donidalorsen was granted orphan designation in the treatment of hereditary angioedem.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IONS:
- Ionis treatment of Pelizaeus-Merzbacher disease granted FDA orphan designation
- Ionis granted orphan status for ALS treatment
- Ionis Pharmaceuticals reports Q2 EPS (60c), consensus (90c)
- Ionis reports second quarter 2023 financial results
- IONS Upcoming Earnings Report: What to Expect?
Questions or Comments about the article? Write to editor@tipranks.com